Press Releases Nykode Therapeutics

Equities

VACC

NO0010714785

Market Closed - Oslo Bors Other stock markets 11:04:14 2024-05-13 am EDT			5-day change	1st Jan Change
14.05 ^NOK	+0.07%		+0.50%	-34.35%

Apr. 19	Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	MT
Apr. 19	Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nykode Therapeutics : Remuneration Report 2023	Apr. 19	PU
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider	23-10-27	AQ
Nykode Therapeutics : 2Q 2023 Financial Results – presentation	23-08-23	PU
Nykode Therapeutics : ABGSC Life Science Summit 30-31 May 2023 – presentation	23-06-07	PU
Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer	23-06-01	GL
Nykode Therapeutics to Present at Jefferies Healthcare Conference	23-05-30	GL
Nykode Therapeutics : 1Q 2023 Financial Results – presentation	23-05-12	PU
Nykode Therapeutics : Nomination Committee Proposal	23-04-20	PU
Nykode Therapeutics : Final Results from the Phase 2 VB-C-02 trial – presentation	23-04-19	PU
Nykode Therapeutics : ESG Report 2022	23-04-19	PU
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer	23-04-18	GL
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer	23-04-18	AQ
Nykode Therapeutics : Remuneration Guidelines	23-04-13	PU
Nykode Therapeutics : 4Q 2022 Financial Results – presentation	23-02-28	PU
Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023	23-02-22	GL
Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer	23-02-10	GL
Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference	23-02-07	GL
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference	22-12-23	GL
Nykode Therapeutics : Nycode Therapeutics – Clinical development plan for VB10.16 – presentation	22-12-20	PU
Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers	22-12-20	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nykode Therapeutics

Equities

VACC

NO0010714785

Press Releases

Filters